Notice of Distribution Model for Qinlock™

This notice provides information for 340B covered entities regarding the distribution of Qinlock™ (ripretinib) 50mg.

<table>
<thead>
<tr>
<th>PRODUCT NAME</th>
<th>NDC</th>
<th>STRENGTH</th>
<th>PACKAGE SIZE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qinlock™ (ripretinib) 50mg</td>
<td>73207-0101-30</td>
<td>50mg</td>
<td>Bottle of 90 Tablets</td>
</tr>
</tbody>
</table>

Qinlock is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Deciphera has developed a limited distribution plan through an authorized network of specialty pharmacies and specialty distributors that are equipped to facilitate consistent and efficient delivery of Qinlock, as well as ensure patient care.

Deciphera’s in-network specialty pharmacy and specialty distributor partners are as follows:

Specialty Pharmacies (U.S.)
- Biologics by McKesson
- PANTHERx Rare
- US Bioservices

Specialty Distributors
- ASD Healthcare
- Cardinal SPD
- McKesson Plasma and Biologics (MPB)
- McKesson Specialty Health (MSH)
- Oncology Supply

Contact information for these specialty distributors or by calling (877)-473-6776.

Deciphera’s specialty distributors will be contractually limited, to sell Qinlock to authorized customers, which may include certain authorized physician and oncology practices with in-office dispensing capability, staff model HMO who will take possession, government purchasers and the limited specialty pharmacies identified above. 340B entities may purchase Qinlock through Deciphera’s authorized specialty distributors.

Deciphera offers the 340B ceiling price to all covered entities, except free-standing cancer hospitals, critical access hospitals, rural referral centers, and sole community hospitals, per 42 U.S.C. § 256b(e), due to Qinlock being designated by FDA for orphan use.

Deciphera takes its obligations under the 340B program seriously and makes every effort to ensure that Qinlock is available to eligible 340B covered entities at the applicable statutory ceiling price, in a manner that is no more restrictive than it is for non-340B entities.

The distribution model described above is consistent with section 340B(a)(1) of the Public Health Service Act, which requires manufacturers to “offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price.”

If you have any questions regarding access to Qinlock, please contact Lisa Kiniklis at 708-386-4482.